KRYS:NSD-Krystal Biotech Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 164.83

Change

0.00 (0.00)%

Market Cap

USD 4.71B

Volume

0.90M

Analyst Target

USD 78.88
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-22 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+8.00 (+2.01%)

USD 120.60B
REGN Regeneron Pharmaceuticals Inc

+13.28 (+1.89%)

USD 84.94B
ARGX argenx NV ADR

+4.50 (+0.72%)

USD 36.54B
ALNY Alnylam Pharmaceuticals Inc

-3.18 (-1.30%)

USD 31.66B
BGNE BeiGene Ltd

+1.20 (+0.68%)

USD 20.24B
UTHR United Therapeutics Corporatio..

+4.07 (+1.13%)

USD 16.18B
MRNA Moderna Inc

+0.20 (+0.51%)

USD 16.10B
RPRX Royalty Pharma Plc

+0.33 (+1.32%)

USD 15.27B
SMMT Summit Therapeutics PLC

+0.80 (+4.48%)

USD 13.67B
INCY Incyte Corporation

+1.00 (+1.45%)

USD 13.52B

ETFs Containing KRYS

SBIO ALPS Medical Breakthrough.. 3.59 % 0.50 %

-0.01 (-0.03%)

USD 0.11B
PSCH Invesco S&P SmallCap Heal.. 0.00 % 0.29 %

-0.09 (-0.03%)

USD 0.19B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 32.86% 79% B- 82% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 32.86% 79% B- 81% B-
Trailing 12 Months  
Capital Gain 33.11% 78% C+ 82% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 33.11% 78% C+ 81% B-
Trailing 5 Years  
Capital Gain 167.41% 91% A- 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 167.41% 91% A- 91% A-
Average Annual (5 Year Horizon)  
Capital Gain 40.40% 75% C 84% B
Dividend Return 40.40% 75% C 84% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 34.32% 78% C+ 55% F
Risk Adjusted Return 117.69% 100% F 99% N/A
Market Capitalization 4.71B 94% A 87% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.